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Brazil is one of the 22 countries that concentrates 80% of global tuberculosis cases concomi-
tantly to a large number of hepatitis C carriers and some epidemiological risk scenarios
are  coincident for both diseases. We  analyzed tuberculosis cases that occurred during -
interferon-based therapy for hepatitis C in reference centers in Brazil between 2001 and 2012
and reviewed their medical records. Eighteen tuberculosis cases were observed in patients
submitted to hepatitis C -interferon-based therapy. All patients were human immuno-
deﬁciency virus-negative. Nine patients (50%) had extra-pulmonary tuberculosis; 15 (83%)
showed signiﬁcant liver ﬁbrosis. Hepatitis C treatment was discontinued in 12 patients (67%)
due to tuberculosis reactivation and six (33%) had sustained virological response. The major-
ity  of patients had a favorable outcome but one died. Considering the evidences of -IFN
interference over the containment of Mycobacterium tuberculosis,  the immune impairment
of  cirrhotic patients, the increase of tuberculosis case reports during hepatitis C treatment
with atypical and severe presentations and the negative impact on sustained virological
response, we think these are strong arguments for latent tuberculosis infection screeningbefore starting -interfero
regimens against hepatiti
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Tuberculosis (Tb) is an air-borne infectious disease caused
by the Mycobacterium tuberculosis, considered priority for
surveillance and treatment by the World Health Organization
because of its high incidence and mortality rates, especially in
countries with socio-economic and sanitary issues.
Brazil is one of the 22 countries in the world that concen-
trate 80% of global Tb cases, ranking 16th in absolute number
of cases (71,123 cases in 2013) and 22nd in incidence rate (35.4
cases/100,000 inhabitants). Most of the reported cases occur
among men  in the age group from 40 to 59 years, with pul-
monary presentation (86%).1
Some groups are more  susceptible to Tb than the gen-
eral population, such as patients living with the human
immunodeﬁciency virus/acquired immunodeﬁciency syn-
drome (HIV/Aids), patients under immunosuppressive or
immunobiological therapy as with rheumatic, inﬂammatory
bowel disease, and also in diabetis, chronic kidney disease,
and solid organ transplanted patients.
The treatment of Tb with rifampicin, isoniazid and pyraz-
inamide was adopted in Brazil until 2009. From 2010 on, the
drug regimen containing rifampicin, isoniazid, pyrazinamide,
and ethambutol was adopted. Alternative therapy is recom-
mended for patients with liver diseases or aminotransferases
abnormalities, including streptomycin, oﬂoxacin, and etham-
butol (SOE).2
The standard therapy for chronic hepatitis C has changed
signiﬁcantly during the years. Initially patients were treated
with conventional interferon. When pegylated interferon
became available patients had a more  convenient and effec-
tive therapy with a duration of 24–48 weeks depending on
the hepatitis C virus (HCV) genotype and ﬁbrosis stage. In
special situations such as end-stage renal disease (ESRD) iso-
lated IFN was recommended due to the high risk of hemolytic
anemia induced by ribavirin. This association of drugs could
also lead to a relative immunosuppression. Nowadays several
direct acting antiviral drugs (DAA) are available with high cure
rates, shorter duration of treatment, and fewer adverse events.
Even in this new era of CHC treatment, IFN will still be used
in some situations such as genotype 3 infection and rescue
therapy for non-responders.3
Hepatitis C patients treated with -interferon (-IFN) and
ribavirin are not yet characterized as a more  susceptible group
for developing Tb, although it is already known that there is
an increase on hepatitis C prevalence among Tb patients when
compared to the general population.4 Indeed, some epidemio-
logical risk scenarios are coincident for both diseases, such as
incarceration, homelessness, and drug addiction.1 Other risk
factors for Tb such as undernourishment and relative immun-
odepression can also be induced by -IFN-based hepatitis C
treatment.5
To the extent of our knowledge, at least 16 Tb cases during
or soon after interferon-based hepatitis C therapy in non-HIV
patients were reported in 15 articles so far, some of them
describing severe outcomes of tuberculosis reactivation.6–15
The aim of the present study was to analyze 18 cases of
Tb observed in reference centers for hepatitis C treatment in
Brazil, country with a high prevalence of Tb and an expressive
3number of hepatitis C carriers (2–3 million people).
We  retrospectively analyzed the records of all treated
patients for hepatitis C which were seen monthly during 1 6;2  0(2):205–209
therapy and identiﬁed, based on the signs and symptoms, the
occurrence of Tb cases under various clinical presentations
in patients submitted to -IFN-based therapy for hepatitis C
(pegylated or not).
Patients were evaluated between 2001 and 2012, in four ref-
erence centers in Brazil (two in Sao Paulo, one in Rio de Janeiro
and one in Maranhao where the peak of incidence of tubercu-
losis during this period was 43.7/100,000 in 2001, 93.9/100,000
in 2001 and 47/100,000 in 2002, respectively).16 Cases were
considered related to hepatitis C treatment when diagnosed
during or within six months after the end of treatment.
Once the cases had been identiﬁed, their medical records
were reviewed to obtain epidemiological, clinical, laboratory,
and therapeutic characteristics related to hepatitis C and Tb
and the data about the decision to interrupt treatment. This
decision was made by clinical judgment based on the severity
of the disease.
This study reports secondary data from a main study
approved by the Ethics Committee for Clinical Research of the
main study center.
We identiﬁed 18 cases of Tb in our study, with an incidence
rate of 809 cases/100,000 treated patients.
The majority of patients were male (78%), with a mean age
of 49 ± 10 years; 15 patients (83%) had signiﬁcant liver ﬁbrosis,
including six (33%) with cirrhosis; HCV genotype 1 was the
most frequent (78%). The mean time under hepatitis C treat-
ment until the onset of Tb symptoms was 33 ± 15 weeks. The
mean hemoglobin level on Tb diagnosis was 12.1 ± 4.2 g/dL and
the mean of neutrophil counts was 3596 ± 1938 cells/mm3.
Most patients were treated for hepatitis C with double
therapy, including -IFN (pegylated or not) associated with
ribavirin (89%). The treatment was discontinued early in 67%
of cases because of Tb onset. In an intention to treat approach,
only six patients (33%) achieved sustained virological response
(SVR), while ﬁve relapsed (RR), and the remaining were non-
responders (NR).
At least nine patients (50%) had other risk factors for
Tb development (diabetes mellitus, chronic kidney disease,
tobacco smoking, or alcohol intake). Both Diabetes mellitus and
chronic kidney disease coexisted in 17% of Tb cases. Cirrho-
sis was present in 33% of cases. The most frequent clinical
presentation was pulmonary Tb, in 50% of cases, with half of
patients developing extra-pulmonary Tb. Only one of cirrhotic
patients had extra-pulmonary Tb (pleural effusion) concomi-
tantly to pulmonary disease.
Symptoms and signs of Tb usually appeared during the
third and fourth trimesters of treatment (83% of cases). Three
patients presented Tb after concluding -IFN therapy (two
after three and one after six months of the end of treatment).
Details of treatment for hepatitis C and Tb are shown in
Table 1 and clinical presentation of Tb in Table 2. Nine patients
were treated with the association of rifampicin, isoniazid
and pyrazinamide, adopted in Brazil until 2009 for Tb treat-
ment. From 2010 on, the drug regimen containing rifampicin,
isoniazid, pyrazinamide, and ethambutol was  adopted, what
explains its predominance in the four cases identiﬁed betweenThe 18 Tb cases reported in this study rise the possibility
of a higher risk for infection in patients under -IFN-based
therapy for hepatitis C.
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Table 1 – Clinical/epidemiological characteristics of patients who  developed tuberculosis during or soon after hepatitis C
treatment.
Case Gender Age
(years)
Liver
ﬁbrosis
(METAVIR)
Genotype Therapeutic
regimen for
hepatitis C
Outcome of
hepatitis C
Risk factors
for Tba
Drug
regimen
for Tb
Outcome of
Tb
1 Mb 50 2 1 IFNpeg2bc/RBVd SVRe RHZEf,g,h,i Cure without
sequelae
2 M 59 2 1 IFNpeg2aj/RBV Death DMk,
former
smoker
RHZE Death
3 Fl 58 2 1 IFNpeg2b/RBV SVR RHZE Cure with sequelae –
ventriculoperitoneal
shunt
4 M 40 4 3 IFNm/RBV NRn Previous
Pulmonary
Tb, former
DAo
SOEp,q,i Cure without
sequelae
5 M 52 1 1 IFN NR CKDr,
smoker
S, Ets, E, Z Cure without
sequelae
6 M 66 4 1 IFNpeg2a/RBV NR RHZ/SOE Cure without
sequelae
7 F 50 3 1 IFNpeg2b/RBV RRt RHZ/SOE Cure without
sequelae
8 M 65 4 1 IFNpeg2a/RBV SVR SOE Cure without
sequelae
9 F 52 1 1 IFNpeg2a/RBV RR RHZ Cure without
sequelae
10 M 44 4 3 IFNpeg2b/RBV RR Alcohol
intake
RHZ Cure without
sequelae
11 M 52 2 3 IFN/RBV NR DM RHZ Cure without
sequelae
12 M 28 1 1 IFN alone RR CKD RHZE Cure without
sequelae
13 M 40 2 1 IFNpeg2a alone RR CKD RHZ Cure without
sequelae
14 F 55 4 1 IFN/RBV NR DM RHZ/SOE Cure without
sequelae
15 M 53 4 1 IFN/RBV SVR RHE Cure without
sequelae
16 M 41 2 1 IFNpeg2b/RBV NR AIu, former
DA
RHZE Cure without
sequelae
17 M 32 2 3 IFNpeg2b/RBV SVR RHZ Cure without
sequelae
18 M 47 2 1 IFNpeg2a/RBV SVR RHZ Cure without
sequelae
a Tuberculosis.
b Male.
c Pegylated -interferon 2b.
d Ribavirin.
e Sustained virological response.
f Rifampicin.
g Isoniazid.
h Pyrazinamide.
i Ethambutol.
j Pegylated -interferon 2a.
k Diabetes mellitus.
l Female.
m Standard -interferon.
n Non-responder.
o Drug addict.
p Streptomycin.
q Oﬂoxacin.
r Chronic kidney disease.
s Ethionamide.
t Response and relapse.
u Alcohol intake.
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Table 2 – Clinical aspects and diagnostic methods of tuberculosis cases.
Case Symptoms and signs Damaged organs Diagnostic methods
1 Fever, axillary lymphadenopathy,
asthenia, myalgia
Lymph  node Lymph node biopsy
2 Fever, diarrhea, asthenia, night sweats,
nausea, gait disorder
Disseminated Bone marrow biopsy
3 Arthralgia, irritability, transient cognitive
deﬁcit
Central nervous system Cerebrospinal ﬂuid examination
4 Fever, cough, chills, bronchospasm Lungs Chest radiography, positive sputum
smear microscopy
5 Fever, cough Lymph node Lymph node biopsy
6 Fever, cough, fatigue, weight loss, anemia,
leukopenia, thrombocytopenia,
hemoptysis
Lungs  Symptoms and positive tuberculin
skin test
7 Fever, cough, asthenia, anorexia, myalgia,
arthralgia, weight loss, anemia,
leukopenia
Lungs  Positive sputum smear microscopy
8 Cough, asthenia, anemia, leukopenia Lungs Positive sputum smear microscopy
9 Fever, weight loss, loss of appetite,
asthenia, night sweats, chest pain,
anemia, leukopenia
Lungs Chest radiography and CTa
10 Fever, cough, weight loss, dyspnea, chest
pain
Pleura and lungs Pleural ﬂuid examination, Chest CT
11 Fever, cough, weight loss Lungs Chest radiography
12 Thoracolumbar pain Spine Spine CT – Pott’s disease
13 Ascites, weight loss Peritoneum Ascites ﬂuid examination
14 Fever, cough Lungs Chest radiography
15 Left wrist pain Bone/joint Histopathology
16 Night sweats Lungs Positive sputum smear microscopy
17 Cough Lungs and relapse in lymph
node
Positive sputum smear microscopy
18 Fever, cough, chest pain Pleura and lungs Chest radiography, pleural ﬂuid
examinationa Computerized tomography.
In a population-based study conducted in Taiwan, an
endemic Tb area, Lin et al., 2014 studied the incidence rates
of active tuberculosis in HCV-infected patients with (n = 621)
or without (n = 2460) interferon-based therapy (IBT). They
observed a non statistically signiﬁcant increased hazard of
active Tb in HCV infected patients on IBT in one-year follow-
up.17 Moreover, they mention that the investigators had no
access to other important Tb risk factors, detailed laboratory
results, and medication records. They also consider that some
patients could have died before being registered in the Health
Insurance Research Database due to Tb infection or taking
medications for that condition, underestimating the number
of cases. The magnitude of 809 cases/100,000 treated patients
is more  impressive when the data are compared to the inci-
dence of Tb cases in the Brazilian population in 2013 (35.4
cases/100,000 inhabitants). Other groups, traditionally a pri-
ority for Tb control, such as the indigenous people, have a
lower incidence (94.5 cases/100,000 inhabitants) when com-
pared to our report.1 On the other hand, comparable incidence
rates had been described in renal transplant patients: 803
cases/100,000 patients.18
Most patients were male within the age group of
1higher prevalence of Tb in Brazil. Diabetes mellitus and
chronic kidney disease coexisted in less than 20% of cases,
comorbidities widely known to increase the risk of active
tuberculosis.19 Cirrhosis, also blamed as a risk factor for Tb,20was present in one third of cases. Half of the cases were extra-
pulmonary tuberculosis, more  compatible with a situation
of immunosuppression, since in non-immunosuppressed
subjects only 15–20% of extra-pulmonary forms are
expected.21
We  observed a high discontinuation rate of IBT due to the
onset of Tb; one third of patients achieved SVR. On case two,
the acute onset of Tb symptoms and severe and fatal outcome
of the disease in less than 60 days, bring the possibility of bac-
teremia and sepsis caused by M.  tuberculosis in an early phase
of infection.15
On the previous case reports the authors discussed many
mechanisms of association between hepatitis C treatment
and Tb reactivation. They suggested that IFN can induce an
impairment of the early immune response against M. tuber-
culosis, speciﬁcally observed on severe cases, besides the role
of leukopenia, neutropenia, a lowering on T-CD4+ lymphocyte
population and abnormalities on chemotaxis and phagocytic
functions of macrophages5,8,10,11,15.
We would like to emphasize that many  studies had already
showed that - and -IFN inhibit type I immune response
which is characterized by lL-12, -IFN and TNF- production,
cytokines that restrain M.  tuberculosis. This inhibition could
lead to LTBI reactivation,22 as occurred on most cases reported
here, including the three cases in which Tb appeared after
stopping hepatitis C treatment. We  consider that there was a
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esidual immune effect of -IFN that can last until 16 weeks
fter the last dose administered.
In summary, considering the evidences of -IFN interfer-
nce over the constrainment mechanisms of M.  tuberculosis,
he immune impairment of cirrhotic patients, the increase
f Tb case reports during hepatitis C treatment, as in this
xpressive retrospective study, with atypical and severe pre-
entations, and the negative impact on SVR, we think that
hese are strong arguments for LTBI screening by tuberculin
kin test and/or by interferon gamma releasing assays, before
tarting -IFN-based therapy. This is even more  important
n countries with high Tb incidence and in more  susceptible
opulations in which epidemiological determinants of both
iseases can coexist and interact. In these medium or low
ncome countries the use of -IFN-based therapy will still per-
ist for some time before it is possible to extend the use of
irect-acting antivirals (DAA) for hepatitis C. DAA should be
onsidered if a patient tests positive for LTBI. Furthermore,
ven in the direct active antivirals era, the inclusion of patients
n the treatment of hepatitis C is an opportunity for LTBI
creening.
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